| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ernest Choy | |
| Blerina Kola | |||
| Ryan DeMasi | |||
| Sadiq Lula | |||
| Michael Nurmohamed | |||
| Paola Accossato | |||
| P2860 | cites work | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study | Q24630541 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 | ||
| The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data | Q30680371 | ||
| Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis | Q82847957 | ||
| Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab | Q82930139 | ||
| No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment | Q83430670 | ||
| Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study | Q83753675 | ||
| TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice | Q84565491 | ||
| Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis | Q84751886 | ||
| Tocilizumab increases EPC regeneration in rheumatoid arthritis | Q85313522 | ||
| Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis | Q86520150 | ||
| Tofacitinib versus methotrexate in rheumatoid arthritis | Q88103514 | ||
| ??? | Q28295371 | ||
| Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. | Q33436848 | ||
| 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis | Q34027648 | ||
| Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy | Q34162072 | ||
| Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results | Q34219694 | ||
| HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab | Q34270268 | ||
| 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis | Q34500921 | ||
| Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). | Q34768442 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis | Q35170882 | ||
| Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. | Q35200354 | ||
| Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources | Q35318027 | ||
| Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study | Q35352554 | ||
| The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases | Q35533763 | ||
| Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients | Q35540000 | ||
| Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial | Q35605487 | ||
| Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis | Q35638180 | ||
| The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab | Q35675593 | ||
| Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy | Q35676074 | ||
| Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | Q35877149 | ||
| Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis | Q35954510 | ||
| Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy | Q36151574 | ||
| Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease | Q36677345 | ||
| Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists | Q36742762 | ||
| Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study | Q36761766 | ||
| Macrolide antibiotics and the risk of ventricular arrhythmia in older adults | Q36808701 | ||
| Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients | Q37130018 | ||
| A general framework for the evaluation of clinical trial quality | Q37223882 | ||
| Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis | Q37245188 | ||
| Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib | Q37257476 | ||
| Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37808889 | ||
| Cardiovascular risk and the use of biologic agents in rheumatoid arthritis | Q38260198 | ||
| Cardiovascular comorbidity in rheumatic diseases | Q38568465 | ||
| Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis | Q38951238 | ||
| Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 | ||
| Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years | Q40639756 | ||
| Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan | Q40879218 | ||
| Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis | Q40959053 | ||
| Chronic inhibition of tumor necrosis factor-α with infliximab improves myocardial deformation in parallel with aortic elasticity in rheumatoid arthritis | Q42474358 | ||
| Effect of Long-Term TNF-α Inhibition with Infliximab on Left Ventricular Torsion in Patients with Rheumatoid Arthritis. | Q42483149 | ||
| Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial | Q42611547 | ||
| Effects of infliximab treatment in terms of cardiovascular risk and insulin resistance in ankylosing spondylitis patients | Q43482103 | ||
| Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study | Q43686388 | ||
| Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results | Q43957207 | ||
| Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | Q44165611 | ||
| The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis | Q44558171 | ||
| Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis | Q45251969 | ||
| Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. | Q45939167 | ||
| Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. | Q46003173 | ||
| Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis | Q46085062 | ||
| Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients | Q46477622 | ||
| Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. | Q46521163 | ||
| Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis | Q46714949 | ||
| Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody | Q46757443 | ||
| Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients | Q47743748 | ||
| Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial | Q49218023 | ||
| Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. | Q51009674 | ||
| Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. | Q51464070 | ||
| Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. | Q51695204 | ||
| The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial. | Q53095551 | ||
| Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. | Q53249650 | ||
| Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy | Q57819586 | ||
| Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis | Q58912330 | ||
| Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis -- A Randomized Trial | Q59123639 | ||
| Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis | Q60061984 | ||
| Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism | Q60241022 | ||
| Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis | Q61830824 | ||
| Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab | Q79170004 | ||
| Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st | Q79765442 | ||
| Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate | Q80201780 | ||
| A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases | Q80241608 | ||
| A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone | Q82066071 | ||
| The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass | Q82404260 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| rheumatism | Q684924 | ||
| pyrimidine | Q47069735 | ||
| pyrrole | Q67954132 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 473-488 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review | |
| P478 | volume | 41 |
Search more.